You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國藥現代(600420.SH):國藥致君產品注射用頭孢曲松鈉三個規格擬中選第五批全國藥品集採
格隆匯 06-23 18:24

格隆匯6月23日丨國藥現代(600420.SH)公佈,2021年6月23日,公司的控股子公司國藥集團致君(深圳)製藥有限公司(“國藥致君”)參加了國家組織藥品集中採購和使用聯合採購辦公室(以下簡稱“聯採辦”)組織的第五批全國藥品集中採購工作。國藥致君產品注射用頭孢曲松鈉0.25g、0.5g、1.0g三個規格擬中選此次集中採購,擬中選價格分別為12.38元/盒、21.05元/盒、35.78元/盒。

公司上述產品2020年度銷售收入合計約4,268.00萬元,佔公司2020年度營業收入約0.34%。根據此次《全國藥品集中採購文件》(GY-YD2021-2)精神,本輪公司擬中選藥品的採購週期原則上為3年,採購週期中,醫療機構將優先使用此次藥品集中採購中選藥品,並確保完成約定採購量。

此次公司產品擬中選價格具體以聯採辦公佈的價格為準。若確定中選、後續簽訂購銷合同並實施後,將有利於增強產品競爭力,提高市場佔有率,提升公司的品牌影響力,對公司的未來經營業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account